9 Meters Biopharma (Nasdaq:NMTR) - 주가, 뉴스 및 분석

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NMTR 주식 개요

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. 자세한 내용

NMTR 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

보상

수익은 연간 56.58% 증가할 것으로 예상됩니다.

위험 분석

의미 있는 시가총액이 없습니다. ( $3M )

cash runway 경력이 1년 미만입니다.

수익이 1백만 달러 미만인 경우 ( $0 )

마이너스 주주 지분

+ 3 더 많은 위험

9 Meters Biopharma, Inc. 경쟁사

SenesTech

NasdaqCM:SNES

US$2.4m

Akanda

NasdaqCM:AKAN

US$2.3m

InMed Pharmaceuticals

NasdaqCM:INM

US$3.3m

China Pharma Holdings

NYSEAM:CPHI

US$3.8m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 9 Meters Biopharma
과거 주가
현재 주가	US$0.20
52주 최고치	US$6.56
52주 최저치	US$0.18
베타	1.48
11개월 변경	-72.75%
3개월 변경 사항	-85.45%
1년 변경 사항	-96.00%
33년 변화	-98.32%
5년 변화	-99.85%
IPO 이후 변화	-99.83%

최근 뉴스 및 업데이트

Recent updates

9 Meters Biopharma to execute 1-for-20 reverse stock split

Oct 17

9 Meters Biopharma GAAP EPS of -$0.04 in-line

Aug 15

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

Jun 14

9 Meters drug effective in treating rare COVID-19 complication in children

May 26

9 Meters Bio gains 5% on Adage Capital stake disclosure

Dec 29

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

Dec 21

9 Meters Bio launches equity offering

Dec 11

주주 수익률

	NMTR	US Pharmaceuticals	US 마켓
7D	-71.1%	3.4%	1.6%
1Y	-96.0%	14.2%	32.3%

수익률 대 산업: NMTR 지난 1년 동안 14.2 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: NMTR 지난 1년 동안 32.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is NMTR's price volatile compared to industry and market?
NMTR volatility
NMTR Average Weekly Movement	22.4%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

안정적인 주가: NMTR 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: NMTR 의 주간 변동성은 지난 1년 동안 17% 에서 22% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	10	Bethany Sensenig	www.9meters.com

9 Meters Biopharma, Inc. 기본 사항 요약

9 Meters Biopharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
NMTR 기본 통계
시가총액	US$2.82m
수익(TTM)	-US$46.28m
수익(TTM)	n/a

0.0x

P/S 비율

-0.1x

P/E 비율

NMTR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
NMTR 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$46.28m
수익	-US$46.28m

최근 보고된 수익

Mar 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-3.20
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	-80.5%

NMTR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

This company listing is no longer active

NMTR 주식 개요

보상

위험 분석

9 Meters Biopharma, Inc. 경쟁사

NasdaqCM:SNES

US$2.4m

NasdaqCM:AKAN

US$2.3m

NasdaqCM:INM

US$3.3m

NYSEAM:CPHI

US$3.8m

가격 내역 및 성능

최근 뉴스 및 업데이트

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

Price target decreased to US$57.00

9 Meters Biopharma to execute 1-for-20 reverse stock split

Price target increased to US$3.40

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma GAAP EPS of -$0.04 in-line

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

Price target decreased to US$3.33

Independent Chairman recently bought US$50k worth of stock

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought US$56k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Price target decreased to US$4.33

President recently bought US$53k worth of stock

President recently bought US$53k worth of stock

Independent Chairman recently bought US$100k worth of stock

Director Sandeep Laumas has left the company

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters drug effective in treating rare COVID-19 complication in children

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: US$1.50

New 90-day high: US$1.37

9 Meters Bio gains 5% on Adage Capital stake disclosure

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

9 Meters Bio launches equity offering

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

New 90-day high: US$0.89

New 90-day high: US$0.85

Independent Chairman recently bought US$96k worth of stock

Independent Chairman recently bought US$56k worth of stock

New 90-day low - US$0.47

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index